ADXS - Advaxis to fund earl-stage ADXS-504 study for prostate cancer

Advaxis (ADXS) announces an agreement with Columbia University Irving Medical Center to fund a Phase 1 clinical study evaluating ADXS-504 in patients with biochemically recurrent prostate cancer.The study, expected to begin in Q2, will evaluate the safety and tolerability of ADXS-504 monotherapy, administered via infusion, in 9-18 patients with recurrent prostate cancer.The trial will also evaluate preliminary clinical and immune responses following treatment with ADXS-504 monotherapy.

For further details see:

Advaxis to fund earl-stage ADXS-504 study for prostate cancer